

# Kai Hu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5116696/publications.pdf>

Version: 2024-02-01

22  
papers

1,114  
citations

566801

15  
h-index

676716

22  
g-index

22  
all docs

22  
docs citations

22  
times ranked

2119  
citing authors

#	ARTICLE	IF	CITATIONS
1	Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. <i>Nature Communications</i> , 2020, 11, 3523.	5.8	357
2	CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 212.	1.8	104
3	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. <i>Nature Communications</i> , 2021, 12, 2893.	5.8	104
4	Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer. <i>ACS Nano</i> , 2020, 14, 5711-5727.	7.3	92
5	Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. <i>Journal of Controlled Release</i> , 2021, 338, 201-210.	4.8	53
6	Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. <i>Virology</i> , 2012, 423, 97-106.	1.1	51
7	DC-SIGN as an attachment factor mediates Japanese encephalitis virus infection of human dendritic cells via interaction with a single high-mannose residue of viral E glycoprotein. <i>Virology</i> , 2016, 488, 108-119.	1.1	48
8	CCL19 and CCL28 Augment Mucosal and Systemic Immune Responses to HIV-1 gp140 by Mobilizing Responsive Immunocytes into Secondary Lymph Nodes and Mucosal Tissue. <i>Journal of Immunology</i> , 2013, 191, 1935-1947.	0.4	43
9	Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA. <i>Molecular Therapy</i> , 2021, 29, 1174-1185.	3.7	40
10	HSV-2 Immediate-Early Protein US1 Inhibits IFN- $\beta$ Production by Suppressing Association of IRF-3 with IFN- $\beta$ Promoter. <i>Journal of Immunology</i> , 2015, 194, 3102-3115.	0.4	37
11	Contribution of N-linked glycans on HSV-2 gB to cell-cell fusion and viral entry. <i>Virology</i> , 2015, 483, 72-82.	1.1	33
12	Tick-Borne Encephalitis Virus Nonstructural Protein NS5 Induces RANTES Expression Dependent on the RNA-Dependent RNA Polymerase Activity. <i>Journal of Immunology</i> , 2018, 201, 53-68.	0.4	30
13	DC-SIGN plays a stronger role than DCIR in mediating HIV-1 capture and transfer. <i>Virology</i> , 2014, 458-459, 83-92.	1.1	22
14	Immunization with HSV-2 gB-CCL19 Fusion Constructs Protects Mice against Lethal Vaginal Challenge. <i>Journal of Immunology</i> , 2015, 195, 329-338.	0.4	16
15	Herpes Simplex Virus Type 2 Infection-Induced Expression of CXCR3 Ligands Promotes CD4+ T Cell Migration and Is Regulated by the Viral Immediate-Early Protein ICP4. <i>Frontiers in Immunology</i> , 2018, 9, 2932.	2.2	16
16	HSV-2 Infection of Human Genital Epithelial Cells Upregulates TLR9 Expression Through the SP1/JNK Signaling Pathway. <i>Frontiers in Immunology</i> , 2020, 11, 356.	2.2	15
17	Presentation of antigen on extracellular vesicles using transmembrane domains from viral glycoproteins for enhanced immunogenicity. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12199.	5.5	14
18	Japanese encephalitis virus counteracts BST2 restriction via its envelope protein E. <i>Virology</i> , 2017, 510, 67-75.	1.1	9

#	ARTICLE	IF	CITATIONS
19	Penton base induces better protective immune responses than fiber and hexon as a subunit vaccine candidate against adenoviruses. <i>Vaccine</i> , 2018, 36, 4287-4297.	1.7	9
20	CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge. <i>MSphere</i> , 2021, 6, .	1.3	8
21	Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. <i>Journal of Virological Methods</i> , 2022, 302, 114475.	1.0	8
22	Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion. <i>Vaccine</i> , 2019, 37, 7501-7508.	1.7	5